New cancer drug tested in humans for first time
NCT ID NCT05821777
Summary
This was an early-stage study to test a new cancer drug called LB101 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology - Dallas
Irving, Texas, 75039, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute at HealthONE.
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at Tennessee Oncology Nashville
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.